Lion Point Capital’s Seres Therapeutics MCRB Stock Holding History

Lion Point Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$249K	Hold	31,570	–	–	1.19%	29
2026 Q1	$280K	Hold	31,570	–	–	1.67%	26
2025 Q4	$470K	Buy	31,570 +4,432	+16%	+$77.3K	2.43%	17
2025 Q3	$522K	Buy	27,138 +10,100	+59%	+$161K	2.97%	17
2025 Q2	$189K	Hold	17,038	–	–	1.29%	18
2025 Q1	$239K	Hold	17,038	–	–	1.52%	18
2024 Q4	$283K	Hold	17,038	–	–	1.48%	18
2024 Q3	$322K	Hold	17,038	–	–	0.72%	21
2024 Q2	$247K	Hold	17,038	–	–	0.45%	21
2024 Q1	$264K	Hold	17,038	–	–	0.15%	25
2023 Q4	$477K	Sell	17,038 -17,552	-51%	-$461K	0.24%	21
2023 Q3	$1.65M	Hold	34,590	–	–	0.73%	11
2023 Q2	$3.31M	Buy	34,590 +4,750	+16%	+$517K	1.5%	8
2023 Q1	$3.38M	Hold	29,840	–	–	1.39%	11
2022 Q4	$3.11M	Sell	29,840 -1,500	-5%	-$201K	0.44%	21
2022 Q3	$3.23M	Buy	31,340 +7,250	+30%	+$743K	0.71%	27
2022 Q2	$2.66M	Hold	24,090	–	–	0.3%	34
2022 Q1	$3.43M	Hold	24,090	–	–	0.8%	24
2021 Q4	$4.01M	Hold	24,090	–	–	1.08%	20
2021 Q3	$3.35M	Buy	+24,090	New	+$4.71M	0.63%	26

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Lion Point Capital's MCRB Position: Q2 2026 in Review

Lion Point Capital held its Seres Therapeutics (MCRB) position steady in Q2 2026 at 31,570 shares worth $249K. The position accounts for 1.19% of the portfolio, ranked #29.

Lion Point Capital first reported a position in MCRB in Q3 2021 and has held it in 20 quarters since. The position peaked at $4.01M in Q4 2021. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

Lion Point Capital held 31,570 shares of Seres Therapeutics worth $249K as of Q2 2026.
Lion Point Capital left its Seres Therapeutics share count unchanged in Q2 2026.
Seres Therapeutics made up 1.19% of Lion Point Capital's portfolio in Q2 2026, its #29 holding.
Lion Point Capital first reported a position in Seres Therapeutics in Q3 2021 and has held it in 20 quarters since.
Lion Point Capital's Seres Therapeutics position peaked at $4.01M in Q4 2021.
35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.